Agios Pharmaceuticals, Inc. (LON:0HB0)

Market Cap	1.60B
Revenue (ttm)	29.15M
Net Income (ttm)	538.15M
Shares Out	n/a
EPS (ttm)	9.30
PE Ratio	2.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233
Average Volume	359
Open	34.32
Previous Close	33.71
Day's Range	33.99 - 34.76
52-Week Range	20.13 - 35.35
Beta	n/a
RSI	51.83
Earnings Date	Feb 13, 2025

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 488
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HB0

Financial Performance

Financial numbers in USD